Nanjing Lingnuo Biopharmaceutical Technology Research Institute

Lingnuo Pharmaceutical is a clinical-stage biotechnology company based in Nanjing, China, specializing in the development of innovative therapies for rare diseases and complement-mediated disorders. The company focuses on the complement system, leveraging its proprietary platform to design long-acting inhibitors that aim to improve patient outcomes and accessibility. Its lead candidate, LN001, is a long-acting monoclonal antibody targeting Complement C5, currently in Phase 2 clinical trials for paroxysmal nocturnal hemoglobinuria (PNH). Beyond LN001, the company is advancing a pipeline of candidates targeting other components of the complement cascade, such as Factor B and C3. Founded by industry veterans with deep expertise in complement biology, Lingnuo is positioned to address significant unmet needs in immunology and hematology.